ER/PR(+), HER2(-) BREAST CANCER
Clinical trials for ER/PR(+), HER2(-) BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER/PR(+), HER2(-) BREAST CANCER trials appear
Sign up with your email to follow new studies for ER/PR(+), HER2(-) BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Matched conditions: ER/PR(+), HER2(-) BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New breast cancer surgery could spare women from unnecessary lymph node removal
Disease control Recruiting nowThis study is for women with early-stage luminal breast cancer that has spread to 1 or 2 lymph nodes. Instead of removing many lymph nodes from the armpit, surgeons will remove only the marked suspicious node and the sentinel nodes. If fewer than 3 nodes are positive, full lymph …
Matched conditions: ER/PR(+), HER2(-) BREAST CANCER
Sponsor: European Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC